SeekingAlpha · Aug 26, 2026
Cullinan Therapeutics: A Self-Funding Bridge To Immune Reset
Cullinan Therapeutics offers a unique, multi-asset portfolio with near-, mid-, and long-term value drivers. Find out why CGEM stock is a buy.
CG
NASDAQ · CGEM
Cullinan Therapeutics, Inc.
Healthcare · Medical - Pharmaceuticals
$21.00
Down-$0.31 (-1.45%)
Updated Sep 11, 2026, 3:05 AM
SID Score
6.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 730.18M
- P/E ratio
- -3.35
- Dividend yield
- 0.00%
- 52-week range
- $11.68 – $23.19
- Volume
- 805.67K
- Avg. volume
- 1.2M
Price performance
CGEM price history
1M range · 20 trading sessions · Daily adjusted prices
CGEM closed at $21.00 after 20 trading sessions, up 6.92% for the selected period.
- Last close
- $21.00
- Period change
- +6.92%
- Period low
- $19.64
- Period high
- $22.95
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | $20.99 | $21.215 | $20.495 | $21.00 | 805.67K |
| Sep 9, 2026 | $21.30 | $21.795 | $21.08 | $21.31 | 1.28M |
| Sep 8, 2026 | $21.61 | $22.4101 | $21.28 | $21.69 | 953.74K |
| Sep 4, 2026 | $21.88 | $22.30 | $21.77 | $22.09 | 562.49K |
| Sep 3, 2026 | $22.39 | $22.68 | $21.65 | $22.16 | 524.12K |
| Sep 2, 2026 | $21.88 | $22.79 | $21.75 | $22.33 | 769.69K |
| Sep 1, 2026 | $21.80 | $22.07 | $21.55 | $21.79 | 546.14K |
| Aug 31, 2026 | $21.50 | $22.23 | $21.34 | $22.07 | 682.98K |
| Aug 28, 2026 | $22.60 | $22.88 | $21.565 | $21.70 | 630.09K |
| Aug 27, 2026 | $22.55 | $22.958 | $22.185 | $22.60 | 471.91K |
| Aug 26, 2026 | $22.66 | $23.19 | $22.42 | $22.85 | 683.47K |
| Aug 25, 2026 | $22.16 | $23.06 | $22.155 | $22.95 | 519.26K |
| Aug 24, 2026 | $21.62 | $22.3699 | $21.1564 | $21.82 | 617.37K |
| Aug 21, 2026 | $21.72 | $22.11 | $21.40 | $21.68 | 758.22K |
| Aug 20, 2026 | $22.14 | $22.25 | $21.02 | $21.38 | 902.53K |
| Aug 19, 2026 | $21.48 | $22.54 | $21.2201 | $22.52 | 707.19K |
| Aug 18, 2026 | $20.23 | $21.20 | $19.99 | $20.84 | 595.22K |
| Aug 17, 2026 | $20.02 | $21.22 | $19.90 | $20.59 | 894.69K |
| Aug 14, 2026 | $19.31 | $20.37 | $18.58 | $20.34 | 565.88K |
| Aug 13, 2026 | $20.72 | $21.00 | $18.775 | $19.64 | 1.8M |
Latest CGEM news
The latest Smart Investors Daily articles mentioning CGEM.
Stock researchCompany · Overview
CGEM research
Overview
Company profile and research snapshot.
Company profile
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $32.67
- Implied upside
- —
- Analysts
- 17
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 13, 2026 | Wedbush | Outperform | — |
| Jul 29, 2026 | BTIG | Buy | — |
| Jun 11, 2026 | Wedbush | Outperform | — |
| Jun 8, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 19, 2026
Taiho Oncology And Cullinan Therapeutics Say Results From Planned Interim Analysis Of Phase 3 REZILIENT3 Trial Selected For Presentation In Presidential Symposium 2 At IASLC 2026 World Conference On Lung Cancer
Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial, which met its primary endpoint of progression-free survival in first line EGFR exon 20 insertion mutation NSCLCTaiho
Benzinga · Aug 17, 2026
HC Wainwright & Co. Reiterates Buy on Cullinan Therapeutics, Maintains $30 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $30 price target.
Benzinga · Aug 13, 2026
Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape
Cullinan Therapeutics and Taiho report positive Phase 3 trial results for zipalertinib in treating advanced lung cancer.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
